Evidence map›Paper›PMID 41782339›Full record

ArticleAnnals of medicine2026

Hypertension management in transition: gains, gaps, and growing challenges in a high-altitude multi-ethnic region of China (2019-2024).

Tingxin Li, Ping Shuai, Maolin Chen, Jing Zhao, Yue Li, Qichuan Qiao, Ruixuan Hou, Zixuan Wang, Xing Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tingxin LiDepartment of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Ping ShuaiDepartment of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Maolin ChenSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jing ZhaoWest China School of Public Health, Sichuan University, Chengdu, China.
Yue LiDepartment of Geriatric center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Qichuan QiaoDepartment of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Ruixuan HouChengdu University of Traditional Chinese Medicine, Chengdu, China.
Zixuan WangSchool of Public Health, Guizhou Medical University, Anshun, China.
Xing ChenDepartment of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.ORCID 0009-0006-9512-7267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension remains a major public health challenge in China, particularly in socioeconomically transitioning regions. This study aims to evaluate changes in hypertension prevalence, awareness, treatment, and control rates between 2019 and 2024 in a Tibetan-predominant area of Sichuan Province.

methodsTwo cross-sectional surveys were conducted in 2019 (

resultsAge-standardized hypertension prevalence decreased significantly from 22.86% to 15.53%. Awareness, treatment, and control rates all improved markedly, from 24.63% to 53.43%, 16.08% to 43.93%, and 3.98% to 17.37%, respectively. Health inequities narrowed substantially between urban and rural areas and between genders. However, absolute control rates remained suboptimal (18.14% in 2024). Rising obesity prevalence (5.11% to 11.44%) and persistent gaps in treatment quality were observed.

conclusionsSubstantial progress in hypertension management and health equity was observed in the area between 2019 and 2024. However, persistently low control rates and rising obesity highlight the need to enhance treatment quality and implement integrated cardiovascular risk reduction strategies. These findings provide important insights for chronic disease management in similar transitioning regions.

Indexed as

HypertensionAgedAltitudeAntihypertensive AgentsChinaCross-Sectional StudiesFemaleHumansMaleMiddle AgedObesityPrevalenceAntihypertensive Agentscross-sectional surveyHypertensioninverse probability weightingprimary health care

Identifiers

PMID41782339
PMCPMC12964464

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.